COMPANY PROFILE

Slate Medicines

Explore full profile

Anti-PACAP monoclonal antibody for migraine prevention

Raleigh, United StatesFounded 2026Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Slate Medicines

Slate Medicines is a biotechnology company developing next-generation therapeutics targeting PACAP for the prevention and treatment of migraines and related headache disorders. The company focuses on injectable therapies, including monoclonal antibodies, with potential at-home administration. Led by experienced biopharma executives, Slate aims to advance innovative migraine treatments where previous approaches have struggled, leveraging licensed assets and proprietary research to build a pipeline of headache disorder therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2026
Headquarters: Raleigh, United States
Employees: 7
Open positions: None listed
Dealroom signal: 84.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Antibodies, Chronic Disease, Clinical Trials, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Feb 2026	$130M	$520M	Forbion Capital Partners · Foresite Capital · RA Capital Management	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Slate Medicines website traffic

Latest recorded traffic for Slate Medicines is 2.7K monthly website visits.

Latest monthly visits2.7K

Monthly website visitsJun 2026–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PRProAbtechSite-specific bioconjugation for enhanced, long-acting biological drugs.	Gwangju, South Korea	Operational	—	$20M	$50M
NMnQ MedicalNeurotechnology company allowing data defined disease management via typing signatures	Cambridge, United States	Operational
SBSparian BiosciencesClinical-stage biopharmaceuticals targeting CNS disorders with novel compounds and strategic collaborations	New York City, United States	Operational
ETEikonizo TherapeuticsDeveloping therapies to improve the treatment of human disease, specifically neurodegenerative diseases	Cambridge, United States	Operational
BSBi/ond SolutionsEmpowers biological innovation by engineering hardware solutions for cell-based assays	Delft, Netherlands	Closed
RTR1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions	Temecula, United States	Operational
SBShizhiyuan BiotechnologyInnovative monoclonal antibody drug development and manufacturing	China	Operational
FTFidra TherapeuticsMultifunctional antibody drug platform for neurodegenerative disorders	Somerville, United States	Operational